JETCRAFT
24.1.2023 16:58:39 CET | Business Wire | Press release
Jetcraft, the global leader in business aircraft sales and acquisitions, has appointed Gerald Hooper and Laurence Vidal to senior sales roles in the Americas. The executive hires position Jetcraft to meet customer demand throughout the continent and further expand the company’s on-the-ground market intelligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230124005773/en/
Image of Gerald Hooper, Aircraft Sales Director, Jetcraft (Photo: Business Wire)
As Aircraft Sales Director, Hooper will lead Jetcraft’s business development in the US West Coast territories, including Northern California, Oregon, Washington and Idaho. Prior to joining Jetcraft, Hooper was Director of Aircraft Sales and Acquisitions at Executive Aircraft Services (EAS), working with corporate clients and aircraft worldwide.
Based in Brazil, Vidal joins Jetcraft as Sales Representative and will oversee the South American territories, including Chile, Argentina, Uruguay, Brazil, Bolivia and Paraguay. Vidal has held positions at leading OEMs, including an eight-year tenure at Bombardier Aerospace where she formulated business strategies to drive market share in the Brazilian executive aviation market.
Dan Kilkeary, SVP Sales, Americas at Jetcraft, says: “With more than 40 years combined experience in business aviation, Gerald and Laurence bring extensive local and industry knowledge to Jetcraft and will ensure we continue to exceed client expectations across the Americas.
“Our latest Market Forecast highlights the importance of our presence in these regions, with North America continuing to lead demand for pre-owned business jets across the globe, growing from 53% market share in 2010 to 73% in 2021 in terms of aircraft value. South America business jet activity is also soaring, with business aviation flights up 23% compared to 2022, according to data from WingX.”
Gerald Hooper, Aircraft Sales Director at Jetcraft, says: “This is an exciting time to join Jetcraft as business aviation continues to grow across North America. Jetcraft’s priority is bringing creative global solutions to the West Coast and I’m eager to begin closing transactions for our clients.”
Laurence Vidal, Sales Representative at Jetcraft, adds: “I’m ready to support Jetcraft in executing complex aircraft sales, acquisitions and trades, while providing a personal, inclusive service and fostering long-term relationships across South America.”
Hooper and Vidal’s appointments follow two senior executive appointments in 2022, upping Jetcraft’s headcount to more than 80.
ENDS
About Jetcraft
More than brokers, Jetcraft® is a network of global aircraft advisors, offering unmatched international reach and unrivalled local knowledge. The company’s market leading intelligence, strategic financing solutions and extensive inventory support even the most intricate of transactions. For 60 years Jetcraft has led the way, setting standards that continue to shape the industry. Today, a team of 80+ dedicated aviation specialists across 25+ offices deliver worldwide aircraft sales, acquisitions and trading at the speed of life.
www.jetcraft.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005773/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom